BGB-45035
- Generic Name
- BGB-45035
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases
Phase 1
Recruiting
- Conditions
- Healthy ParticipantsHealthy SubjectsHealthy VolunteersAutoimmune DiseasesHealthy Adult ParticipantsAtopic DermatitisPrurigo Nodularis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 195
- Registration Number
- NCT06342713
- Locations
- 🇦🇺
Innovate Clinical Research, Waitara, New South Wales, Australia
🇦🇺Cmax Clinical Research, Adelaide, South Australia, Australia
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath